Compare J B Hunt Transport Services Inc (JBHT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Novavax Inc — how do they compare? J B Hunt Transport Services Inc trades at $227.99 (market cap $21.45B), while Novavax Inc trades at $12.59 (market cap $1.82B). The key difference: J B Hunt Transport Services Inc is far larger — about 11.8× Novavax Inc's market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 45 Days and Novavax Inc for 59 Days on average.
| JBHT | NVAX | |
|---|---|---|
Market Cap | $21.45B | $1.82B |
Volume | 1,028,680 | 6,198,505 |
Sector | Industrials | Health |
52-Week High | $298.41 | $12.56 |
52-Week Low | $137.09 | $6.22 |
Typical Hold Time | 45 Days | 59 Days |
Enterprise Value | $22.59B | $1.39B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $228.99, up 2.85% today, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $12.00B in 2025, with a net income margin of 4.98%, and has beaten EPS estimates in recent quarters. Analyst consensus is a Buy with a $289.40 price target, but news highlights ongoing securities class action investigations.
The outlook is mixed: strong fundamentals and analyst support suggest upside, but technical weakness and legal risks pose headwinds. Investors should weigh earnings growth potential against cost pressures and litigation uncertainties for balanced risk-reward assessment.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
